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The Management of End Stage Liver
Disease in the Correctional Setting
Rachel Maddow*, D.Phil., Joseph Bick**, M.D.

Approximately one-third of hepatitis C- (HCV)
infected persons in the United States passed
through jail or prison facilities in 1997.1 In some
states, the prevalence of chronic HCV infection
among incoming prisoners is as high as 49%
(see Table 1). Correctional healthcare providers
are on the front line in the diagnosis and management of HCV in this country.
Among those with chronic HCV, the natural history of progression from infection to cirrhosis in
an individual patient is uncertain. Ten to 15 percent of those with HCV will develop cirrhosis
within 20 years of initial infection.6,7 Studies evaluating serial liver biopsies in HCV-infected prisoners have demonstrated distinct cohorts of fast,
moderate, and non-progressors.8 Numerous
studies have demonstrated that coinfection with
HIV increases the rate of progression to cirrhosis.
Chronic liver disease and cirrhosis kills more
than 25,000 people in the US annually9 and is
among the 10 leading causes of death for White
males, Hispanics, and Native Americans.10 In
patients with HCV and cirrhosis, the five-year
death rate is approximately 15%.11 In some correctional facilities, end-stage liver disease
(ESLD) is now the leading cause of death among
inmates.12 This article focuses on the treatment
of ESLD in the correctional setting, primarily
among patients with chronic HCV.

Chronic Hepatitis Treatment Some Patients Left Behind?
Advances in combination therapy have improved
clinical options for some patients with chronic
HCV. However, correctional health providers are
still confronted with many patients with cirrhosis
and ESLD. Reasons for this include:
(1) Even under ideal treatment conditions, sustained viral response (SVR) rates for the current
anti-HCV combination therapy (pegylated interferon plus ribavirin) are less than 50% for genotype 1, and less than 80% for other less common
genotypes.13
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TABLE 1: Proportion of persons
entering state prisons found to have
HCV infection
California:2
Maryland:3
Massachusetts:4
Texas:5

WOMEN
39%
39%
44%
49%

MEN
32%
25%
27%
27%

(2) Many people cannot tolerate anti-HCV combination therapy because of side effects, co-morbidities (including psychiatric issues), or other
factors.
(3) Prisoners are eight to 10 times more likely
than the general population to be HIV-infected.14
Coinfection with HIV is estimated to reduce SVR
rates for anti-HCV combination therapy by 20 to
30%, though some of this difference may be due
to adherence issues.15 As highly active antiretroviral therapy (HAART) has reduced HIV-related
morbidity and mortality among HIV-infected persons, ESLD has risen in importance as a cause
of death among people with HIV/AIDS16 (see
Table 2).
(4) Prisoners in the US are disproportionately
African American, and HCV treatment response
rates are lower among African Americans than
among other racial groups. This treatment disparity has not been adequately explained, and is
now the subject of a major federal study.18
(5) Some correctional healthcare systems do not
routinely offer HCV testing or treatment for
inmates. The number of such systems is expectContinued on page 2
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Management of End
Stage... (continued from page 1)
ed to decline now that the Centers for
Disease Control and Prevention (CDC) has
published guidelines for managing viral
hepatitis in correctional settings.19

Diagnosis of Viral Hepatitis
and Cirrhosis
The first step in the diagnosis of liver disease due to viral hepatitis is to offer antibody
screening for hepatitis B and C (HBV, HCV).
Some clinicians recommend targeted
screening based upon risk factor histories.
In many correctional systems, the prevalence of chronic hepatitis among inmates is
sufficiently high and the reliability of risk factor history information is sufficiently low that
all inmates should be offered testing for both
viruses.
Most of those infected with HBV will spontaneously clear the virus and be left with antibodies to the viral surface and core antigens. Approximately 5% will develop chronic HBV. Unlike HBV infection, 60-85% of
those with HCV infection will develop chronic disease.20 Chronic infection with HCV can
be confirmed by detection of HCV RNA in
the plasma.
Among those with chronic viral hepatitis, no
single test or panel is sufficient to accurately portray disease severity. A basic lab
assessment for patients with liver disease
should include complete blood counts
(CBC), serum aminotransferase levels (ALT
and AST), bilirubin, albumin, prothrombin
time/INR, and platelet count. Serial measurements over time offer a more complete
portrait of the severity progression of the disease than individual assays. Elevated
AST/ALT values reflect inflammation, while
prolonged INR and decreased albumin can
reflect decreased hepatic function. Elevated
direct bilirubin may be indicative of cirrhosis
or bile duct obstruction; total bilirubin levels
over approximately 2.5 mg/dl are associated
with jaundice. Anemia can be due to variceal
bleeding, while thrombocytopenia can result
from bleeding or sequestration in an
enlarged spleen.
Physical examination of patients with
advanced liver disease may detect a firm
and enlarged liver, though in very advanced
cirrhosis, the liver may decrease in size.
External physical examination may also
detect excess fluid in the abdomen by palpating the flanks and feeling for a shifting
wave of fluid. Imaging techniques such as
ultrasound, CT scan, and MRI can reveal
ascites, an enlarged spleen, reversed portal
vein flow, and hepatocellular carcinoma
(HCC).

2

visit HEPP Report online at www.hivcorrections.org
TABLE 2: Before and after HAART: ESLD as a cause of death in
HIV-infected persons17
Setting

Pre-HAART Era
#/%
Year

HAART Era
#/%

Year

Brescia, Italy

305/13%

1987

46/35%

1996

Madrid, Spain

312/5%

1991-5

20/45%

2000

Boston, MA (USA)

36/12%

1991

22/50%

1998-9

Paris, France

1327/2%

1995

543/8%

1997

Liver biopsy is the single best technique for
determining disease progression, and is the
definitive means of confirming cirrhosis and
assessing its severity.21 Liver biopsy has
become a contentious issue in corrections
because of cost and the high number of
patients with chronic viral hepatitis. Despite
advances in noninvasive monitoring techniques, biopsy remains the gold standard for
the assessment of severity of cirrhosis.22,23,24
Most of those with serially "normal" ALTs will
have minimal inflammation, are likely to be
to be slow progressors, and may not need to
undergo biopsy. Just as HCV treatment
costs may be reduced by price negotiation25,
it may be possible to reduce biopsy costs by
proactively contracting for biopsies based
on HCV prevalence in the facility or system
in question. Correctional health providers in
Pennsylvania have reportedly reduced biopsy costs to as low as $400 per patient.26 At
the California Medical Facility in the
California DOC, on site biopsy costs are less
than $300 per patient.27

Pathophysiology and
Complications of Cirrhosis
Damage to the liver due to chronic alcohol
or other toxins, infection, obstruction, or
heart failure can lead pathologic changes
including fibrosis and the formation of regenerative nodules. These pathologic changes
are termed cirrhosis, and can result in a variety of clinical manifestations. When the liver
is cirrhotic but still able to perform most
basic functions, cirrhosis is referred to as
"compensated". Further loss of functioning
hepatocytes can result in "decompensated"
cirrhosis, manifest by coagulopathy, jaundice, and edema. Extensive fibrosis can
cause portal hypertension, splenomegaly,
and gastroesophageal varices. In more
severe cases, patients may develop excess
fluid within the peritoneal cavity (ascites),
spontaneous bacterial peritonitis, and/or
encephalopathy. Up to 5% of those with cirrhosis will develop HCC. Deaths associated
with HCV are more likely to be due to complications of decompensated cirrhosis such
as variceal bleeding, encephalopathy, and
peritonitis, than to HCC.28

Portal hypertension: When scar tissue
obstructs the normal flow of blood through
the liver, pressure within the liver's main
blood vessel, the portal vein, is increased.
Portal hypertension is responsible for common complications of ESLD, including
variceal bleeding and ascites.
Variceal bleeding: When blood cannot flow
normally through the portal vein, it must
return to the heart using other blood vessels.
These other blood vessels, called varices,
enlarge to provide an alternative pathway for
blood diverted from the liver. Varices often
form in the stomach and esophagus. They
pose a high risk for rupture and bleeding
because they are thin-walled, often abnormally twisted and swollen, and subject to
high pressure. Internal variceal bleeding
occurs in 20 to 30% of cirrhotic patients and
is dangerous, with mortality rates reported
between 15 and 50%.29 Vomiting blood or
passing black stools can be signs of variceal
bleeding.
Ascites: Lowered albumin production from
the cirrhotic liver and other physiological
processes can result in fluid retention in the
peritoneal cavity. Ascites itself is not lifethreatening, but it is a marker of severe disease progression. The probability of death
within two years in cirrhotic patients hospitalized with ascites is approximately 40%,
and is worse for those who develop spontaneous bacterial peritonitis (SBP), a common
and potentially fatal complication of
ascites.30
Encephalopathy: The exact pathogenesis
of hepatic encephalopathy is not clear. A
build-up of toxins such as ammonia can
affect the brain, causing confusion, memory
loss, fatigue, agitation, and possibly coma
and death. Early symptoms of encephalopathy can include confusion, drowsiness,
lethargy, and difficulty concentrating. The
physical examination in those with
encephalopathy may demonstrate tremor,
asterixis, and slowed coordination.
Hepatorenal syndrome: Hepatorenal syndrome is a potentially life-threatening complication of liver disease in which patients
Continued on page 4
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Faculty Disclosure

Letter from the Editor
Dear Colleagues:
I am reminded of the problems addressed in this issue of the HEPP Report every time I visit the
inpatient ward of my facility. Several of our ID clinic patients have become long-term residents of
that ward, simply because their liver disease cannot be safely managed in the outpatient correctional setting. I have had to revisit published literature in order to learn to manage these patients
more effectively. This issue of HEPP Report was conceived with that need for an update in mind
- we’ve now provided you (and me!) with the latest information on the management of inmates
presenting with chronic hepatitis and cirrhosis.
Unfortunately, HCV-related liver disease is only likely to become even more common in correctional settings as time goes on. While the incidence of HCV (the rate of new infections) is slowly
decreasing, HCV-related liver disease is becoming more common as HCV infections "mature".
The prevalence of HCV-related liver disease is expected to peak in the year 2010 both inside and
outside of correctional settings. Given the fact that the cost for hospitalizations related to HCV in
the United States was 1.6 billion dollars in 1998, 10 to 12 years before the expected peak, it is
clear that we are about to witness a major shift in prison health care expenditures.
Given that potential scenario, aggressive treatment of HCV-infected patients in correctional environments should be viewed as potentially cost saving. One decision analysis study has demonstrated that HCV treatment resulted in a net savings in the range of $400 to $3500 over the lifetime of each patient, in the same range of cost effectiveness as stool guiac testing, pneumococcal vaccination, coronary bypass surgery, and mammography. According to a more recent publication, combination HCV therapy resulted in improvements in Quality Adjusted Life Year (QALY)
for both men and women. QALY measures improvements in health-related quality of life, meaning less chronic illness and fewer laboratory tests and clinic visits. These are the same types of
benefits that have been observed over the past 10 years following improvements in HIV care.
More aggressive management of HCV infection in the near term may therefore affect the "bottom
line" for correctional health care in years to come.
My visits to the inpatient ward in my facility hint at our collective future. We anticipate that this
issue of HEPP Report will provide you with an overview of prevention, diagnosis and treatment
of viral hepatitis and cirrhosis, and approaches that may be efficacious in preventing common
complications of end-stage liver disease.
And let us not forget to celebrate the season! The entire staff of HEPP Report wishes you a wonderful holiday and a happy and healthy 2004!
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Management of End
Stage... (continued from page 2)
develop oliguria, hyponatremia, hypotension, and renal failure manifest by increases
in BUN and creatinine. The exact etiology of
this syndrome is not clear, but it can be precipitated by sepsis, severe variceal bleeding,
aggressive diuresis or paracentesis.
Patients with advanced cirrhosis also commonly develop malnutrition, gallstones, and
coagulopathy due to impaired hepatic
synthesis of clotting factors and thrombocytopenia.

Prevention and Treatment
of Complications
The prevention and treatment of complications associated with ESLD can be challenging for even experienced generalist physicians. In general, the management of those
with ESLD should be done in consultation
with a gastroenterologist or hepatologist. In
one recent study, hospitalized patients with
decompensated cirrhosis managed by a
generalist in consultation with a gastroenterologist fared better than patients managed by generalists alone. Better outcomes
included shorter length of hospitalization,
lower cost of hospitalization, lower rates of
hospital readmission, and improved survival.31
Patients with chronic hepatitis should be
protected from further hepatic insult. Those
who are not immune to hepatitis A and
hepatitis B should be vaccinated.32 Those
with liver disease should receive annual
influenza vaccinations and a pneumococcal
vaccine. Patients should avoid hepatotoxic
medications whenever possible. Large
doses of acetominophen should be avoided,
however, low doses (less than 2,000 milligrams per day) are generally well-tolerated.
Non-steroidal anti-inflammatory drugs such
as ibuprofen (Advil®), naproxen (Aleve® or
Naprosyn®), or aspirin should be used with
caution both because of hepatotoxic potential and the risk for bleeding. The dosage of
medications that are hepatically metabolized
may need to be adjusted. Because of the
increased prevalence of HIV infection
among those with viral hepatitis, patients
should also be encouraged to test for HIV.
Alcohol
Because alcohol is commonly covertly manufactured and ingested in prison, all patients
should be educated about the extreme
importance of avoiding alcohol. Even moderate ingestion of alcohol hastens the progression of liver disease in those with cirrhosis. Correctional physicians should link their
patients to drug and alcohol abuse treatment

visit HEPP Report online at www.hivcorrections.org
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programs both within the correctional system and at the time of release.

TABLE 3:
Signs and Symptoms of Cirrhosis

Nutrition
Maintaining adequate nutrition for patients
with advanced liver disease can be difficult
in the community, and poses particular challenges in the prison setting. Adequate
dietary protein is important for patients with
ascites and for repairing lost muscle mass.
However, excess protein may pose a risk for
encephalopathy. In those prone to
encephalopathy, vegetable proteins may
pose fewer risks than animal proteins. Iron
supplementation and excessive sodium
intake should be avoided in those with cirrhosis. Patients with ascites may require
fluid and salt restriction.

Many patients with cirrhosis have no
symptoms, and are only determined to
be cirrhotic by physical examination
and liver biopsy. When signs or symptoms are present, they can include:

Variceal bleeding
Beta-blockers can reduce heart rate, lower
portal vein pressure, and reduce the threat
of variceal bleeding. Patients with diabetes,
asthma, emphysema and chronic bronchitis
may be unable to tolerate beta-blockers.
Options for treatment of variceal bleeding
and prevention of recurrence also include
endoscopic scleropathy, vasoactive drugs,
and band ligation. Surgical shunts and
Transjugular Intrahepatic Portosystemic
Shunt (TIPS) are other options to eliminate
variceal bleeding. TIPS is a less invasive
procedure in which the shunt is inserted
through a catheter.
Ascites
Patients with ascites may require a reduced
salt diet, reduced fluid intake, and diuretics.
Spironolactone in doses of 100-400 milligrams per day can be used to achieve
diuresis. In those who fail to respond to
diuretics, fluid may be drained with a
catheter or plastic drainage tube inserted
into the abdominal wall (paracentesis).
Paracentesis should be accompanied by
albumin infusion to prevent circulatory dysfunction and other complications.33 TIPS is
also an option in ascites patients for whom
paracentesis is ineffective, intolerable, or
contraindicated.34
Bacterial Peritonitis
Patients with SBP may present with fever,
hypotension, abdominal discomfort, and/or
encephalopathy. Often the clinical findings
are very subtle, and the clinician must act
presumptively to prevent death of the
patient. Gram stain and culture of ascitic
fluid often fails to demonstrate the presence
of an organism. To diagnose SBP, ascitic
fluid should be examined by microscope and
inoculated directly into blood culture bottles.
An ascitic fluid neutrophil count of 250 polymorphonuclear cells/mm3 is diagnostic of
SBP.30 In suspected cases, treatment should

w
w
w
w
w
w
w
w
w
w

enlargement of the liver
loss of appetite
unusual weight loss or weight gain
nausea and vomiting
fatigue
jaundice
enlargement of the spleen
abdominal swelling
swelling of the legs
amenorrhea (absence of menstrual
periods)
w intense itching
w vomiting blood
w palmar erythema (reddish and
blotchy palms)
w loss of body hair
w spider angiomas (pinhead-sized red
spots on the skin with tiny visible
blood vessels, blanch with pressure)
be initiated with cefotaxime, ceftriaxone, or a
fluoroquinolone. Patients who have already
had a previous episode of SBP are at high
risk for recurrence, and should be provided
prophylaxis with trimethoprim -sulfamethoxazole, ciprofloxacin, or norfloxacin.
Encephalopathy
Precipitating factors for encephalopathy in
advanced liver disease can include gastrointestinal bleeding, excess dietary protein,
constipation, or infection. The goal of treatment for encephalopathy is to lower the level
of toxic substances affecting the brain by
reducing or eliminating dietary protein and
removing nitrogenous material from the gut,
often by using lactulose.35
Fulminant hepatic failure is manifest as
encephalopathy, worsening jaundice, gastrointestinal bleeding, sepsis, coagulopathy,
hypoglycemia, renal failure, and electrolyte
abnormalities. Patients with fulminant hepatic failure should be managed in the ICU setting, and should urgently be evaluated for
candidacy for liver transplant.36
Transplantation
More than 3,000 liver transplants are performed annually in the US. For patients with
cirrhosis, the two commonly used indices of
liver disease severity are Child-TurcottePugh (CTP) and Model for End Stage Liver
Disease (MELD). CTP and MELD are
designed to direct organ allocation to liver
transplantation candidates based on the
Continued on page 5
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severity of disease. CTP score is determined using albumin, bilirubin, prothrombin
time
(INR),
ascites,
and
hepatic
encephalopathy. MELD score is determined
using bilirubin, creatinine, and INR. MELD
uses a wider range of assay values and a
more complicated formula than CTP. A
MELD calculator is available online at the
website of the United Network for Organ
Sharing: www.unos.org. Every correctional
system should have policies in place that
address the appropriate evaluation and
referral of selected patients for consideration
for transplant.
Anti-HCV Maintenance Therapy
There is little clinical basis for recommendations about continued anti-HCV therapy in
patients
with
advanced
cirrhosis.
Nevertheless, some studies have shown
that patients with compensated cirrhosis can
achieve high rates (43%) of SVR on combination therapy,37 and that anti-HCV therapy
may cause histological improvement even in
patients who are virological non-respon-
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ders.38 Whether or not treatment of compensated cirrhotics will translate into decreased
morbidity, improved quality of life, or prolonged survival remains to be seen.
Anti-HCV treatment of patients with decompensated cirrhosis may raise significant
safety issues and should not generally be
recommended except in the setting of clinical trials.
Hepatocellular Carcinoma (HCC)
Chronic HCV infection is a major risk factor
for HCC. The risk for HCC is greatest among
patients with at least 20 years of HCV infection, cirrhosis or advanced fibrosis, male
sex, older age, HBV coinfection, and heavy
alcohol use.39 One to 6% of cirrhotic patients
develop HCC annually.40 Screening techniques for HCC in cirrhotic patients are
serum alpha-fetoprotein (AFP) testing (twice
yearly) and hepatic ultrasound or CT.
Surgical liver resection and liver transplant
are the main treatment strategies for HCC.
Alternative approaches include percutaneous alcohol injection, arterial chemoembolization, or radiofrequency ablation.41

DISCLOSURES: *Nothing to disclose, **Nothing to disclose.
REFERENCES:
1. Hammett TM et al. The Burden of Infectious Disease among Inmates
of and Releasees from US Correctional Facilities, 1997. AJPH 2002
92(11):1789-1794.
2. Fox et al. Prevalence of Hepatitis C in a Sample of California Prison
Inmates. Society of General Internal Medicine 25th Anniversary Meeting,
Atlanta, GA, May 2-4, 2002.
3. AIDS Administration and Division of Correction, State of Maryland.
Final Report: Examination of HIV, Syphilis, Hepatitis B and Hepatitis C in
Maryland Correctional Facilities. March 2003.
4. Massachusetts Public Health Association "Correctional Health: The
Missing Key to Improving the Public's Health and Safety" Boston: MPHA.
October 2003.
5. Baillargeon J, et al. Hepatitis C Seroprevalence among Newly
Incarcerated Inmates in the Texas Correctional System. Public Health
2003 117(1):43-8.
6. National Institutes of Health Consensus Development Conference
Statement "Management of Hepatitis C: 2002" Final Statement. August
2002. See also Ghany et al "Progression of Fibrosis in Chronic Hepatitis
C" Gastroenterology 124(1):97-104.
7. Some practitioners use a fibrosis index (fibrosis stage divided by number of years infected) to divide patients into rapid, intermediate, and slow
progressors (see Cassidy W "Hepatitis C Infections in Prison" HCV
Advocate Medical Writers' Circle: June 2003).
8. Cassidy WM. Treating Hepatitis C in Prisons. Proceedings of the
Management of Hepatitis C in Prisons Conference; 2003 Jan 25-26; San
Antonio, Texas.
9. Anderson RN. Deaths: Leading causes for 1999. National vital statistics reports 49(11):8. Hyattsville,Maryland: National Center for Health
10. National Center for Health Statistics. Health, United States, 2003.
Hyattsville, Maryland: NCHS. 2003. Table 32.
11. Degos et al . Hepatitis C Virus Related Cirrhosis: Time to Occurrence
of Hepatocellular Carcinoma and Death. Gut 47(1):131-6. July 2000.
12. Personal communication, Joseph Bick, MD: Chief Medical Officer,
California Medical Facility, California Department of Corrections.
13. National Institutes of Health Consensus Development Conference
Statement "Management of Hepatitis C: 2002" Final Statement. August
2002.
14. National Commission on Correctional Health Care. Report to
Congress: The Health Status of Soon-to-be-Released Inmates. Chicago:
NCCHC. 2002.

5

Palliative Care, Compassionate Release
Patients with ESLD, especially those who
are not candidates for liver transplantation,
should be considered for hospice care and
compassionate parole or release. Patients
dying with ESLD report a high pain burden,
comparable to that of patients dying with
lung and colon cancer.42 Physicians working
with such patients should be aware of available palliative care options, and should initiate compassionate release or medical
parole proceedings where appropriate.

Conclusions
Over the past 20 years, correctional healthcare providers have become increasingly
important in our nation's response to tuberculosis and HIV. With one-third of HCVinfected individuals in the US passing
through our jails and prisons, correctional
clinicians are now faced with a new challenge. As we become experts in the antiviral treatment of those with chronic hepatitis,
we must also be cognizant of the management of those with ESLD. By doing so, we
can decrease ESLD associated morbidity
and prolong the lives of our patients suffering with this serious illness.
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Dosing of pegylated interferon for the treatment of hepatitis C infection
Pegasys® (pegylated interferon alfa-2a) and CopegusTM (Ribavirin, USP) dosing recommendations
HCV Genotype

Pegasys Dose

Copegus Dose

Duration

1 or 4

180 µg subcutaneously once a
week

<75 kg: 1000 mg daily in two
divided doses

48 weeks

>75 kg: 1200 mg daily in two
divided doses
2 or 3

180 µg subcutaneously once a
week

800 mg daily in two divided
doses

24 weeks

PEG-IntronTM (pegylated interferon alfa-2b) monotherapy dosing recommendations
The recommended dose of PEG-IntronTM regimen is 1.0 µg/kg/week for one year. The volume of PEG-Intron to be
injected depends on the vile strength used and the patient’s weight. (See table below)
Amount of PEG-Intron (µg)
to administer

Volume (mL)* of PEGIntron to administer

50 µg per 0.5 mL

40
50

0.4
0.5

57-72
73-88

80 µg per 0.5 mL

64
80

0.4
0.5

89-106
107-136

120 µg per 0.5 mL

96
120

0.4
0.5

137-160

150 µg per 0.5 mL

150

0.5

Body weight (kg)

PEG-Intron vial strength

<45
46-56

*When reconstituted as directed

PEG-IntronTM (pegylated interferon alfa-2b) and Rebetol® (Ribavirin, USP) dosing recommendations
When administered in combination with Rebetol®, the recommended dose of PEG-IntronTM is 1.5 µg/kg/week. The volume
of PEG-IntronTM to be injected depends on the vile strength used and the patient’s weight. The recommended dose of
Rebetol® is 800 mg/day in two divided doses. (See table below)
Body weight (kg)

PEG-Intron vial strength

Amount of PEG-Intron (µg)
to administer

Volume (mL)* of PEGIntron to administer

<40

50 µg per 0.5 mL

50

0.5

40-50
51-60

80 µg per 0.5 mL

64
80

0.4
0.5

61-75
76-85

120 µg per 0.5 mL

96
120

0.4
0.5

>85

150 µg per 0.5 mL

150

0.5

Management of End Stage...
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Spotlight: Methicillin-Resistant Staphylococcus Aureus (MRSA)
Lou Tripoli*, M.D. and Joseph Bick**, M.D.

Infections caused by methicillin resistant Staphylococcus aureus
(MRSA) have long been a problem in hospitals and nursing homes.
Over the past decade, MRSA has also emerged as a cause of skin
and soft tissue infections in the community.1 Not surprisingly, this
organism is now being increasingly recognized as a cause of infections in residents of jails and prisons.2,3,4 This article summarizes
basic concepts of MRSA diagnosis and management and reviews
recent experiences with MRSA in the correctional environment.
Staphylococcus aureus (SA)
Staphylococcus aureus (SA) is a bacterium commonly found on the
skin or in the nose of healthy individuals. Although it is often a colonizer causing no disease, it can be responsible for minor to lifethreatening infections of the skin, bone, blood, heart valves, and
lungs. SA is easily spread by contact with the skin of a person infected or colonized with the bacteria. SA can also be acquired from inanimate objects that have been in contact with a person carrying the
organism.
Methicillin resistant Staphylococcus aureus (MRSA)
Penicillin resistance in SA is due to the production of beta lactamase, an enzyme that breaks down penicillin's beta lactam ring and
renders the drug inactive. Within a few years of the first clinical use
of penicillin in the 1940s, resistance due to beta lactamases was
identified. Within a year of the introduction of the semisynthetic, beta
lactamase-stable, penicillin methicillin in 1960, MRSA strains were
identified. By the 1990s, over half of SA isolated in some hospitals
were MRSA. Nursing homes and other long-term care facilities have
been identified as reservoirs. Risk factors for infection with MRSA
include prolonged hospitalization, having been in an intensive care
unit, contact with other patients who have MRSA, having had
surgery or another invasive procedure, injection drug use, and
underlying illnesses such as diabetes.
Many microorganisms that develop high-level resistance pay a competitive price to carry that antibiotic resistance and are less fit.
However, MRSA appears to be as virulent in its resistant form as it
is in its wild type. Most MRSA infections are minor infections of the
skin that take the form of pustules, furuncles or boils. Generally,
these conditions are mild and self-limited. It is not always necessary
to treat every infection aggressively.
Methicillin resistant strains are resistant to all beta lactam antibiotics,
including penicillins and cephalosporins. In addition, MRSA strains
often carry plasmids that lead to resistance to multiple other antibiotics. Many MRSA strains are susceptible to trimethoprim-sulfamethoxazole and rifampin. Virtually all SA are fully susceptible to
vancomycin. However, the first clinical isolate of SA with reduced
susceptibility to vancomycin was reported from Japan in 1996.5 The
first documented case of infection caused by vancomycin-resistant
S. aureus (VRSA) (vancomycin MIC >32 µg/mL) in a patient in the
United States was reported in 2002.6
Is it just a spider bite?
In the correctional setting, there has been significant amount of misinformation on the "inmate grapevine" that attributes these otherwise
unremarkable lesions to arachnid bites. In reality, spiders rarely bite
people, and most of the bites are inconsequential. Most spiders only
bite when provoked such as when they are trapped in clothing or in
a shoe. Spider bites characteristically occur at areas where the spider might settle in the clothing, such as the waistband. It is unusual
for a spider to bite multiple times.

The brown recluse spider, or Loxosceles reclusa, in particular, has
been blamed for lesions among the incarcerated. Found in the
Midwest and Southeast, this arachnid prefers isolated areas and is
rather shy and timid. It hibernates during the winter, so bites, which
are generally painless, occur between March and October. Following
a bite, the skin may exhibit a urticarial lesion (hive), a papule, or a
pustule. In severe reactions, patients may develop systemic signs
including rash, fever, headache, and other flu-like symptoms. Only a
small proportion of bites become necrotic, and the progression follows a characteristic pattern termed the "red, white, and blue" sign:
a central blister with purple-gray discoloration (in Caucasians), surrounded by a white ring of blanched skin and a much larger halo of
red. If skin breakdown occurs, the site becomes painful, usually progressing to a black eschar and may be slow to heal.
The misinterpretation of minor skin lesions as spider bites has ironically led to actions that potentially increase health risks for many
inmates. The use of chemicals to eradicate the falsely accused spiders only serves to eliminate an ally in the war against mosquitoes,
which are known to carry illnesses such as West Nile virus.
Recent MRSA outbreaks
Outbreaks of MRSA infections are being increasingly recognized in
jails and prisons throughout the country.2,3,4 Factors that may have
contributed to the problem include: limited access to soap or bathing,
mental illness among prisoners leading to poor hygiene, inadequate
laundry procedures, co-payments for medical care which may limit
access to medical care, infrequent collection of wound cultures, and
the misperception that lesions were due to spider bites.
Georgia: In 2001 and 2002, the Georgia Division of Public Health,
the Georgia Department of Corrections, and local health departments investigated outbreaks of MRSA skin infections in three correctional facilities. Risk factors identified included prolonged incarceration, previous antimicrobial use, self-draining of boils, skin laceration (intentional or accidental), washing clothes by hand, and
sharing soap. Beta lactam antibiotics were not uncommonly used,
even after the identification of MRSA. A number of measures were
implemented, with limited success. These included wide spread
screening for skin disease, implementation of standardized antimicrobial treatment recommendations, changes in laundry practices,
inmate education, the use of chlorhexidine containing soaps, and the
use of alcohol-based hand rubs.
Los Angeles: In 2002, the Los Angeles (L.A.) County jail experienced an increase in reports of spider bites. In response, a protocol
was initiated that called for culturing all suspected spider bite
lesions. Between January of 2002 and June of 2003, over 1,600
MRSA skin infections were identified. In collaboration with the L.A.
County Department of Health Services, the jail recommended
changes to include enhanced skin lesion surveillance, standardized
treatment protocols including empiric treatment with non-beta-lactam antimicrobials for all wound infections, inmate hygiene education, environmental cleaning, and more frequent laundry changes.
Texas: In 1996, the Texas Department of Criminal Justice (TDCJ)
implemented a comprehensive set of treatment and prevention
guidelines for MRSA skin infections that included 1) surveillance, 2)
hygiene education for inmates, 3) access to proper wound care, 4)
standardized antimicrobial therapy based on drug susceptibility data
(including directly observed therapy), 5) early treatment of skin disContinued on page 8
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ease, and 6) eradication of MRSA from asymptomatic carriers who
have recurrent MRSA infections. Since 1998, TDCJ has required culturing of all draining skin lesions and reporting of results to the TDCJ
Office of Preventive Medicine. The proportion of SA infections that
were methicillin-resistant increased from 24% (864 of 3,520) in 1998
to 66% (5,684 of 8,633) in 2002. Implementation of guidelines and a
continued multidisciplinary approach to MRSA infections has not led
to substantial decreases in the incidence of MRSA.

Education and Infection Control
Inmates should be educated about personal hygiene, and advised to
avoid touching other persons' wounds or wound drainage. Inmates
should be provided access to soap, showers, and sinks. Clinical staff
that provides wound care should follow Standard Precautions.
Infection control measures can never be overemphasized, as even in
the hospital setting many healthcare professionals neglect hand
washing. The restrooms in many hospitals and public settings are
poorly designed, leading people to re-contaminate their hands immediately after washing them.

Mississippi: An evaluation of MRSA cases at a state prison in
Mississippi revealed that 19 of 21 (90%) of infected inmates with
wound dressings changed their dressings themselves. Fifteen (33%)
of infected inmates reported helping or being helped by other
inmates with wound care or dressing changes. Twenty-six (58%)
reported lancing their own boils or other inmates' boils with fingernails or tweezers; forty (89%) shared personal items (e.g., linen, pillows, clothing, and tweezers) that potentially were contaminated by
a wound.

In an effort to improve hand hygiene, the use of alcohol-containing
antiseptic scrubs is increasingly being encouraged. However, security concerns may lead to these particular disinfectants not being universally embraced in the correctional setting. Surfaces that are used
by multiple people should be routinely decontaminated. Laundry
should be washed in hot water for at least 25 minutes to be sure that
most bacteria have been exterminated. Custody staff should be educated to refer inmates who have even minor-appearing skin infections so that an appropriate evaluation can be performed.

Treatment of MRSA infections
Some correctional systems have developed guidelines for the management of MRSA. In July 2003, the federal Bureau of Prisons
issued guidelines to prevent and control MRSA in correctional facilities7. This document recommends the reporting and tracking of
patients with MRSA and offers a convenient form to do so. In addition, a useful patient education handout can be found at the end of
the document.

The involvement of experts in infection control and infectious diseases can be useful in both managing individual patients and establishing protocols specific to the unique needs of each facility.

(continued from page 7)

Facilities detecting a substantial number of MRSA infections should
implement improved hygiene, infection-control, and treatment practices. Skin lesions should be cultured to determine the infecting
organism. Drainage of abscesses is important to facilitate cure.
Empiric antibiotic selection should be made with MRSA in mind.
Treatment should be adjusted as needed based upon the infecting
organism's antibiotic susceptibility pattern.
Trimethoprim-sulfamethoxazole (Bactrim, Septra) in a dose of one
double-strength tablet twice daily is usually effective in patients who
have MRSA. Some clinicians also add rifampin in a dose of 600 mg
once daily. Due to the rapid development of resistance, rifampin
should not usually be used alone to treat infections due to SA. For
more serious infections, intravenous vancomycin or oral linezolid
may be used. A new antibiotic, daptomycin, (Cubicin™) has recently been approved for treatment of skin infections due to SA.
Daptomycin is given parenterally, and has a spectrum of activity that
includes virtually all Gram-positive organisms including E. faecalis,
E. faecium (including VRE) and SA including MRSA. Daptomycin
should not be used for pneumonia due to higher failure in clinical trials, and should not be relied upon for CNS or bone infections due to
poor penetration of these tissues.
Clinicians are reminded that oral vancomycin is non-absorbable and
is, therefore, not useful in the treatment of skin and soft tissue infections due to SA.
Eradication of nasal carriage
SA and MRSA commonly inhabit the anterior nares of otherwise
healthy asymptomatic individuals. Routine eradication of this carriage is neither efficacious nor recommended. In some cases of
recurrent active disease, clearance of the organism from the nose
can be beneficial. Mupirocin (Bactroban®) ointment, applied to both
anterior nares bid for 5-7 days, is commonly used for this purpose.

Correctional facilities experiencing outbreaks of MRSA should seek
assistance from their local and state health departments. MRSA outbreaks can be reported to CDC (telephone [800] 893-0485) through
state departments of corrections and state health departments.
Preventing MRSA disease in inmates might be an important measure for preventing MRSA in the community outside the correctional
facility. Additional information about MRSA is available at
http://www.cdc.gov/ncidod/hip/aresist/mrsa.htm
In conclusion, the recent experience with MRSA in jails and prisons
reminds us that antibiotic-resistant organisms will continue to be a
significant problem in this country. Lessons learned from the MRSA
experience may also be applicable to other infections to come.
Correctional healthcare providers' responsibility to public health cannot be underestimated. It is important to strengthen our relationships
with outside public health agencies as we strive to contain this growing threat to the health of those patients entrusted to our care.
Disclosures: *Nothing to disclose.
**Nothing to disclose.
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Save the
Dates
HIV Drug Resistance Testing:
Utilizing phenotypic and genotypic tests to optimize therapy
December 18, 2003, 12p EST
This first online seminar in the
series will focus on the use of phenotypic and genotypic information
to manage drug resistance.
Visit: www.phenosense.com/mdr
The 11th Conference on
Retroviruses and
Opportunistic Infection
February 8-11, 2004
San Francisco, California
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
Visit: www.retroconference.org
Management of HIV/AIDS in
the Correctional Setting:
A Live Satellite
Videoconference Series
Albany Medical Center
March 16, 2004
12:30 PM - 3:30 PM EST
CME and Nursing credits available
Visit: www.amc.edu/Patient/hiv/
hivconf/index.htm
Call: 518.262.4674
Email: ybarraj@mail.amc.edu
National HIV/AIDS
Update Conference
March 27-30, 2004
Hyatt Regency Miami
Miami, Florida
Sponsored by American
Foundation for AIDS Research
Email: jessica@fa-events.com
NCCHC: Clinical Updates in
Correctional Health Care
May 22-25, 2004
Hyatt Regency
Chicago, Illinois
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
9th Northeast Correctional
Health Care Conference
May 26, 2004
Sturbridge Host Hotel
Sturbridge, Massachusetts
Call: 781.279.2254
Fax: 781.279.2977
Email: rduhaime@icg-ps.com
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Inside News
Magic Johnson visits California prison for
World AIDS Day
Continuing his commitment to reaching out to atrisk populations, Earvin "Magic" Johnson visited
California Medical Facility in Vacaville, CA on
Dec. 3, 2003. After a private meeting with the
prison's inmate peer educators, Magic spoke to
an appreciative audience of over 600 inmates,
recounting his own personal journey following his
diagnosis with HIV in 1991. The audience
responded enthusiastically to Magic's messages
concerning testing, treatment, and prevention.
Earlier in the week, the prison was host to
Assemblyman Mark Leno, Senator Gloria
Romero, and 35 members of the San Francisco
Gay Men's Chorus. Senator Romero took the
opportunity to call upon the CA DOC to evaluate
the feasibility of distributing condoms to inmates.
Study: Long Term Adefovir in HBeAg
Negative Chronic Hepatitis B Results in
Significant Virological, Biochemical, and
Histologic Improvement
This study presented from the Henry Dunant
Hospital, Athens, Greece and Gilead Sciences
showed that Adefovir dipivoxil (ADV) 10 mg has
demonstrated significant histological, virological,
and biochemical improvement as compared to
placebo (PLB) through 48 weeks of therapy in
HBeAg positive and HBeAg negative patients.
Study authors concluded that Adefovir for 96
weeks resulted in significant and continued
reduction in HBV DNA and ALT; and additional
histologic improvement beyond that seen at week
48. Discontinuation of ADV resulted in loss of
HBV DNA and ALT suppression and reversion of
histologic improvement. Emergence of adefovir
resistance was delayed and infrequent. Adefovir
has a distinct resistance profile from lamivudine.
Marcellin, Patrick et al. 54th AASLD October
2003 Poster 1156.
Sexual Transmission of HCV in Heterosexual
Monogomous Couples
The aim of this study is to determine the potential
for sexual transmission of HCV among monogamous heterosexual couples by identifying the factors (sexual and non-sexual) associated with antiHCV positivity among partners, and the relatedness of virus strains among concordant couples.
The prevalence of anti-HCV among sexual partners of persons with HCV was 4% (95% CI:
2.3%-5.7%) but 40% of partners had discordant
types indicating lack of sexual transmission. The
majority of type concordant couples lacked per-

cutaneous risk factors for HCV, suggesting sex
may be the route of transmission but phylogenetic analysis of viral strains will ultimately determine
whether sexual transmission occurred.
Terrault, NA et al. 54th AASLD. October 2003
Abstract 716.
Weight Loss and Exercise Can Improve
Fibrosis
Obesity is a risk factor for the progression of
fibrosis in chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) and hepatitis C (HCV). The aim of this study was to investigate the longer-term effect of weight loss on liver
biochemistry, serum insulin levels and quality of
life in overweight patients with liver disease and
the effect of subsequent weight maintenance or
regain and to determine factors associated with
successful weight maintenance. It was demonstrated that lifestyle interventions reduced risk
factors associated with progression of liver disease, decreased abnormal liver enzymes,
improved quality of life and in a proportion of
patients improved histological features of liver
injury. Importantly, these changes were achievable and sustainable with relatively small but persistent changes in lifestyle. Treatment of overweight should form an important component of
the management of patients with chronic liver disease.
Hickman, IJ et al. 54th AASLD. October 2003
Abstract 716.
Study: Survival of HIV-Infected Liver
Transplant Recipients
With immune function restoration made possible
by HAART (Highly Active Antiretroviral Therapy),
a study from the University of Pittsburgh evaluated 24 HIV positive subjects with ESLD who were
undergoing Orthotopic liver transplantation
(OLTX). In contrast to the finding of past inferior
survival observed among HIV-infected transplant
recipients, this study found that successful liver
transplantation is possible for HIV-infected subjects, and that for HIV-infected subjects, postOLTX survival with ART is similar to that for HIV
negative subjects. Data from this study provide a
scientific rationale to justify that HIV infection
should no longer be considered an absolute contraindication to transplantation, which is consistent with recent transplantation arguments based
on ethical considerations.
Ragni, MV et al. Journal of Infectious Diseases
188 (2003) pp. 1412-1420.

Resources
For more information on hepatitis:
w www.hivandhepatitis.com/hiv_hcv_co_inf/
080403a.html
w www.cdc.gov/hepatitis
For more information on MRSA:
w www.cdc.gov/ncidod/hip/aresist/mrsa.htm
w www.ojp.usdoj.gov/bjs/prisons.htm

Immunization questions?
w Email nipinfo@cdc.gov
w Call CDC's Immunization Information Hotline

at (800) 232-2522
w Call your state health dept., (phone numbers
at: www.immunize.org/coordinators)
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through July 31, 2004.
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The rate of progression to cirrhosis in those with HCV is
increased in those who are co-infected with HIV.
a) True
b) False
2. Common laboratory abnormalities in those with end-stage liver
disease include:
a) Hypoalbuminemia
b) Prolonged INR
c) Elevated serum ammonia
d) Thrombocytopenia
e) All of the above
3. The percentage of HCV-infected individuals in the US who
spend time in a prison or jail each year is closest to:
a) 5%
b) 15%
c) 30%
d) 50%
4. Approaches that may be efficacious for the treatment of variceal
bleeding include:
a) beta blockers, sclerotherapy, banding of varices
b) ace inhibitors, lactulose, low protein diets
c) beta blockers, low protein diets, paracentesis
5. Risk factors for acquiring methicillin-resistant Staphylococcus
aureus (MRSA) include:
a) Injection drug use, recent surgery and hemodialysis
b) Diabetes, hemodialysis and HIV-infection
c) Spider bites, indwelling catheters or other hardware
d) None of the above
6. Antibiotics that may retain efficacy for the treatment of MRSA
include:
a) vancomycin, linezolid, ceftriaxone
b) vancomycin, trimethoprim-sulfamethoxazole, linezolid
c) vancomycin, trimethoprim-sulfamethoxazole, ticarcillin
d) vancomycin, dicloxacillin, linezolid
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